Investigation of the CYP2C9 Gene polymorphism frequency and its effects on the warfarin dose used by the patients in a population from Iran

Subject Areas :

Farideh Olia ¹ , Morteza Seifati ² , Naghmeh Satarzadeh ³ , Shahriar Dabiri ⁴ , Shima Mirzaie parsa ⁵ , Mohammad Javad Soltani-Banavand ^{6 *}

1 - Department of Biology, Ashk.C., Islamic Azad University, Ashkzare, Iran
2 - Department of Biology, Ashk.C., Islamic Azad University, Ashkzare, Iran
3 - Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran
4 - Pathology Department, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
5 - Department of Biology, Da.C., Islamic Azad University, Damghan, Iran
6 - Faculty of Medicine, Ke.C., Islamic Azad University, Kerman, Iran

Received: 2024-11-23 Accepted : 2025-08-02 Published : 2025-09-13

Keywords: Warfarin, PCR-RFLP, Gene Polymorphism, CYP2C9, Vitamin k ,

Abstract :

Abstract Background & Aims: warfarin is an edible and anticoagulant drug that is used to treat and avoid thrombolytic disorders. Despite its efficacy, this substance has a therapeutic index and the response to it is completely variable. plenty of this drug lead to bleeding and low dose of that lead to poor blood coagulation. The aim of this study was to survey the relationship between dose of usage of warfarin and Gene polymorphism and its relation with age and sex of the patient. Methods: Blood sampling was done intravenously by receiving consent form on a total of 100 people with heart disease who were referred to a medical laboratory in the city of Kerman to perform the PT Test. After DNA extraction the PCR_RFLP method was done on all samples. the frequency of CYP2C9 gene polymorphism and the relationship with the dose of usage of warfarin, age and gender of patients has been investigated. Results: The frequency of observerd genotypes were 1%, 12%, 87%, sequentially CC, TC, TT In the present study. There was meaningful relationship between age and the dose of usage of warfarin (P=0.0001). Data analysis showed that there was no meaningful relationship between variant genotypes CYP2C9 and the dose of usage of warfarin (P=0.999) and also male and female groups in terms of relationship genotype polymorphism (P=0.115). Conclusions: Based on the results it seems that other genes interfere in the usage of warfarin according to genotype of each population.

References:

1. Aithal, G.P., et al., Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. The Lancet, 1999. 353(9154): p. 717-719.
2. Wen, M.S., et al., Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clinical Pharmacology & Therapeutics, 2008. 84(1): p. 83-89.
3. Soltani Banavandi, M.J. and N.J.T.P.J. Satarzadeh, Association between VKORC1 gene polymorphism and warfarin dose requirement and frequency of VKORC1 gene polymorphism in patients from Kerman province. The Pharmacogenomics Journal, 2020. 20(4): p. 574-578.
4. Landefeld, C.S. and R.J.J.T.A.j.o.m. Beyth, Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. The American journal of medicine, 1993. 95(3): p. 315-328.
5. Hirsh, J., et al., Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 2001. 119(1): p. 8S-21S.
6. Stubbins, M.J., et al., Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics and Genomics 1996. 6(5): p. 429-439.
7. Lindh, J.D., et al., Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis. European Journal of Clinical Pharmacology 2009. 65: p. 365-375.
8. Mwer, S., D. Dykes, and H. Polesky, A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids res, 1988. 16(3): p. 1215.
9. Ma, J.D., K.C. Lee, and G.M. Kuo, Clinical application of pharmacogenomics. Journal of pharmacy practice, 2012. 25(4): p. 417-427.
10. Higashi, M.K., et al., Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama, 2002. 287(13): p. 1690-1698.
11. Rieder, M.J., et al., Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine, 2005. 352(22): p. 2285-2293.
12. Takeuchi, F., et al., A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS genetics, 2009. 5(3): p. e1000433.
13. Smith, P., H. Arnesen, and I.J.N.E.J.o.M. Holme, The effect of warfarin on mortality and reinfarction after myocardial infarction. New England Journal of Medicine, 1990. 323(3): p. 147-152.
14. Asinger, R.W., et al., Incidence of left-ventricular thrombosis after acute transmural myocardial infarction: serial evaluation by two-dimensional echocardiography. New England Journal, 1981. 305(6): p. 297-302.
15. Flockhart, D.A., et al., Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. genetics in medicine, 2008. 10(2): p. 139-150.
16. Rettie, A.E., et al., Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics and Genomics 1994. 4(1): p. 39-42.
17. Taube, J., D. Halsall, and T.J.B. Baglin, The Journal of the American Society of Hematology, Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. The American Society of Hematology, 2000. 96(5): p. 1816-1819.
18. Tabatabaei, S.M., et al., Study of polymorphism frequency of 1639G> A gene from VKORC1 in patients with cardiovascular disorders in the northwestern area of Iran. Journal of Arak University of Medical Sciences, 2012. 15(4): p. 40-46.
19. Rad, F., et al., Evaluation of common polymorphism of CYP2C9 in Warfarin-treated patients. The Scientific Journal of Iranian Blood Transfusion Organization 2016. 12(4): p. 340-346.
20. Poopak, B., et al., Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy. International Journal of Hematology-Oncology and Stem Cell Research, 2015. 9(4): p. 185.
21. Liang, Y., et al., Association of genetic polymorphisms with warfarin dose requirements in Chinese patients. Genetic Testing and Molecular Biomarkers, 2013. 17(12): p. 932-936.
22. Borgiani, P., et al., Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Future Medicine, 2007.
23. Caldwell, M.D., et al., Evaluation of genetic factors for warfarin dose prediction. Marshfield Clinic, 2007. 5(1): p. 8-16.
24. Kianmehr, Z., et al., VKORC1 gene analysis of some Iranian sensitive patients to warfarin. Pakistan Journal of Medical Sciences, 2010. 13(18): p. 906.
25. Kameli, R., et al., Association between cytochrome P450 2 C9 and vitamin K epoxide reductase complex subunit 1 polymorphisms with warfarin dose among Iranian patients. Research in Molecular Medicine, 2016. 4(4): p. 38-44.
26. Mazzaccara, C., et al., Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. PloS one, 2013. 8(8): p. e71505.